Caption Management, LLC Fibrogen Inc Call Options Transaction History

Caption Management, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $2.29 Million - $18.9 Million	917,700 Added 530.46%	1,090,700 $2.94 Million
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $2.76 Million - $4.36 Million	173,000 New	173,000 $3.23 Million
Q4 2021 Feb 11, 2022	BUY	$9.93 - $15.39 $64,545 - $100,035	6,500 Added 8.84%	80,000 $1.13 Million
Q3 2021 Nov 12, 2021	SELL	$10.18 - $26.64 $8.14 Million - $21.3 Million	-799,300 Reduced 91.58%	73,500 $751,000
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $16.2 Million - $31.1 Million	872,800 New	872,800 $23.2 Million
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $1.16 Million - $2.09 Million	-37,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $1.39 Million - $1.84 Million	37,500 New	37,500 $1.39 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $1.05 Million - $2.07 Million	-45,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$34.58 - $48.06 $1.04 Million - $1.44 Million	30,000 Added 200.0%	45,000 $1.93 Million
Q2 2019 Aug 13, 2019	SELL	$35.13 - $55.53 $175,650 - $277,650	-5,000 Reduced 25.0%	15,000 $678,000
Q4 2018 Jan 30, 2019	BUY	$37.97 - $60.16 $759,400 - $1.2 Million	20,000 New	20,000 $926,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.